04:38 AM EDT, 04/08/2024 (MT Newswires) -- Boston Scientific ( BSX ) said Monday it has initiated a study of its Faraview software module and Farawave catheter for the treatment of paroxysmal and persistent atrial fibrillation.

The study is targeting to enroll about 30 subjects at several centers in Europe.

The company expects to receive regulatory approval in the US for the Faraview and Farawave systems in H2.

Atrial fibrillation is a heart condition that results in an irregular and abnormally fast heart rate.